Fig. 3From: Pyrotinib combined with apatinib for targeting metastatic non-small cell lung cancer with HER2 alterations: a prospective, open-label, single-arm phase 2 study (PATHER2)Subgroup analyses of objective response rate (A) and progression-free survival (B)Back to article page